Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C C Hook

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Cancer|August 1, 1993
Pineal parenchymal tumors. Clinical, pathologic, and therapeutic aspectsS E Schild, B W Scheithauer, P J Schomberg, et al.
Leukemia|November 11, 2005
Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemiaD Behl, L F Porrata, S N Markovic, et al.
British Journal of Haematology|July 27, 2001
A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasiaR A Mesa, A Tefferi, M A Elliott, et al.
Blood Cancer Journal|April 8, 2022
Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3"K H Begna, X Xu, N Gangat, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Cancer|August 1, 1993
Pineal parenchymal tumors. Clinical, pathologic, and therapeutic aspectsS E Schild, B W Scheithauer, P J Schomberg, et al.
Leukemia|November 11, 2005
Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemiaD Behl, L F Porrata, S N Markovic, et al.
British Journal of Haematology|July 27, 2001
A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasiaR A Mesa, A Tefferi, M A Elliott, et al.
Blood Cancer Journal|April 8, 2022
Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3"K H Begna, X Xu, N Gangat, et al.
Pageof 2